drugset
drugset / Trial / NCT05407220

A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of HCP1904 in Healthy Male Volunteers.

NCT05407220 ↗

Phase 1 Completed 16 enrolled Hanmi Pharmaceutical Company Limited
RandomizedParallel-groupOpen-labelTreatment

Summary

A Randomized, Open-Label, Single-Dose Parallel Study to Evaluate the Pharmacokinetics, Safety and Tolerability of HCP1904 in Healthy Male Volunteers.

Timeline

Start
2022-06-29
Primary completion
2022-07-25
Completion
2022-07-25

Drugs

EvaluationDrugModalityDoseRoute
Subject HCP1904-1 Unknown — —
Subject HCP1904-3 Unknown — —

Indications

No indication recorded.